POST
FUZZYWUZZY
Title: Impact of the COVID-19 pandemic on science and technology
Date: 01/11/2020 10:43:17
ID: 956521024
Fulltext: <td class="diff-addedline"><div>On 4{{nbsp}}May 2020, the [[World Health Organization]] (WHO) organized a [[telethon]] to raise {{US$|8}} billion from forty countries to support rapid development of vaccines to prevent COVID-19 infections, also announcing deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching [[Phases of clinical research#Phase II|Phase II-III clinical trials]]. The '''Solidarity trial for treatments''' is a multinational [[Phases_of_clinical_research#Phase_III|Phase III-IV clinical trial]] organized by the WHO and partners to compare four untested treatments for hospitalized people with severe [[COVID-19]] illness. The trial was announced 18 March 2020, The WHO is also coordinating a multiple-site, international [[randomized controlled trial]] {{snd}} the [[Solidarity trial]] for vaccines {{snd}} to enable simultaneous evaluation of the benefits and risks of different vaccine candidates under clinical trials in countries where there are high rates of COVID-19 disease, ensuring fast interpretation and sharing of results around the world. The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the [[pivotal trial]] stage. </div></td>
Changed Text: <td class="diff-addedline"><div>On 4{{nbsp}}May 2020, the [[World Health Organization]] (WHO) organized a [[telethon]] to raise {{US$|8}} billion from forty countries to support rapid development of vaccines to prevent COVID-19 infections,&lt;ref name="waked"&gt;{{Cite web|title=World leaders urge cooperation in vaccine hunt, raise $8 billion|url=https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|publisher=Yahoo Finance|author=Damon Wake|date=2020-05-04|access-date=2020-05-04}}&lt;/ref&gt; also announcing deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching [[Phases of clinical research#Phase II|Phase II-III clinical trials]].&lt;ref name="who-accel"&gt;{{Cite web|title=Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|publisher=World Health Organization|date=2020-04-27|access-date=2020-05-02|quote=It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale}}&lt;/ref&gt; The '''Solidarity trial for treatments''' is a multinational [[Phases_of_clinical_research#Phase_III|Phase III-IV clinical trial]] organized by the WHO and partners to compare four untested treatments for hospitalized people with severe [[COVID-19]] illness.&lt;ref name="who"&gt;{{cite web |title=UN health chief announces global 'solidarity trial' to jumpstart search for COVID-19 treatment |url=https://news.un.org/en/story/2020/03/1059722 |publisher=United Nations, World Health Organization |accessdate=2 April 2020 |language=en |date=18 March 2020}}&lt;/ref&gt;&lt;ref name="kai"&gt;{{cite news |last1=Kupferschmidt |first1=Kai |last2=Cohen |first2=Jon |title=WHO launches global megatrial of the four most promising coronavirus treatments |url=https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments |accessdate=2 April 2020 |work=Science |publisher=AAAS |date=22 March 2020 |language=en}}&lt;/ref&gt; The trial was announced 18 March 2020,&lt;ref name="who" /&gt; and as of 21 April, over 100 countries were participating.&lt;ref&gt;{{Cite web|url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments|title='Solidarity' clinical trial for COVID-19 treatment|last=|first=|date=|website=www.who.int|publisher=World Health Organization|language=en|url-status=live|archive-url=|archive-date=|access-date=2020-04-22}}&lt;/ref&gt; The WHO is also coordinating a multiple-site, international [[randomized controlled trial]] {{snd}} the [[Solidarity trial]] for vaccines&lt;ref name=who-accel/&gt;&lt;ref name="solidarity-vacc"&gt;{{Cite web|title=An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial|url=https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf|publisher=World Health Organization|date=2020-04-09|access-date=2020-05-09}}&lt;/ref&gt; {{snd}} to enable simultaneous evaluation of the benefits and risks of different vaccine candidates under clinical trials in countries where there are high rates of COVID-19 disease, ensuring fast interpretation and sharing of results around the world.&lt;ref name=who-accel/&gt; The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the [[pivotal trial]] stage.&lt;ref name=who-accel/&gt; </div></td>
Printed Text: <td class="diff-addedline"><div>On 4{{nbsp}}May 2020, the World Health Organization (WHO) organized a telethon to raise {{US$|8}} billion from forty countries to support rapid development of vaccines to prevent COVID-19 infections, also announcing deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching Phase II-III clinical trials. The '''Solidarity trial for treatments''' is a multinational Phase III-IV clinical trial organized by the WHO and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, The WHO is also coordinating a multiple-site, international randomized controlled trial {{snd}} the Solidarity trial for vaccines {{snd}} to enable simultaneous evaluation of the benefits and risks of different vaccine candidates under clinical trials in countries where there are high rates of COVID-19 disease, ensuring fast interpretation and sharing of results around the world. The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonized Phase III protocols for all vaccines achieving the pivotal trial stage. </div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=985995608&oldid=956521024
Previous Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=956521024&oldid=956389432
Fuzzy: On 4 May 2020, the World Health Organization (WHO) organised a telethon to raise US$8 billion from forty countries to support rapid development of vaccines to prevent COVID-19 infections,[6] also announcing deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching Phase II-III clinical trials.[7] The "Solidarity trial for treatments" is a multinational Phase III-IV clinical trial organised by the WHO and partners to compare four untested treatments for hospitalised people with severe COVID-19 illness.[8][9] The trial was announced 18 March 2020,[8] and as of 21 April, over 100 countries were participating.[10] The WHO is also coordinating a multiple-site, international randomised controlled trial—the "Solidarity trial for vaccines"[7][11]—to enable simultaneous evaluation of the benefits and risks of different vaccine candidates under clinical trials in countries where there are high rates of COVID-19 disease, ensuring fast interpretation and sharing of results around the world.[7] The WHO vaccine coalition will prioritize which vaccines should go into Phase II and III clinical trials, and determine harmonised Phase III protocols for all vaccines achieving the pivotal trial stage.[7]



POST
FUZZYWUZZY
Title: Impact of the COVID-19 pandemic on science and technology
Date: 01/11/2020 10:43:18
ID: 956521024
Fulltext: <td class="diff-addedline"><div>The [[Coalition for Epidemic Preparedness Innovations]] (CEPI){{snd}}which is organizing a {{US$|2}} billion worldwide fund for rapid investment and development of vaccine candidates{{snd}}indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021. </div></td>
Changed Text: <td class="diff-addedline"><div>The [[Coalition for Epidemic Preparedness Innovations]] (CEPI){{snd}}which is organizing a {{US$|2}} billion worldwide fund for rapid investment and development of vaccine candidates&lt;ref name="cepi-fund"&gt;{{cite web |title=CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19 |url=https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/ |publisher=Coalition for Epidemic Preparedness Innovations, Oslo, Norway |access-date=23 March 2020 |date=6 March 2020}}&lt;/ref&gt;{{snd}}indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021.&lt;ref name="thanh"&gt;{{cite journal | last=Thanh Le | first=Tung | last2=Andreadakis | first2=Zacharias | last3=Kumar | first3=Arun | last4=Gómez Román | first4=Raúl | last5=Tollefsen | first5=Stig | last6=Saville | first6=Melanie | last7=Mayhew | first7=Stephen | title=The COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery | date=9 April 2020 | issn=1474-1776 | doi=10.1038/d41573-020-00073-5| pmid=32273591 |url=https://www.nature.com/articles/d41573-020-00073-5| name-list-format = vanc }}&lt;/ref&gt; </div></td>
Printed Text: <td class="diff-addedline"><div>The Coalition for Epidemic Preparedness Innovations (CEPI){{snd}}which is organizing a {{US$|2}} billion worldwide fund for rapid investment and development of vaccine candidates{{snd}}indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021. </div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=985995608&oldid=956521024
Previous Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=956521024&oldid=956389432
Fuzzy: The Coalition for Epidemic Preparedness Innovations (CEPI)—which is organising a US$2 billion worldwide fund for rapid investment and development of vaccine candidates[12]—indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021.[13]



POST
FUZZYWUZZY
Title: Impact of the COVID-19 pandemic on science and technology
Date: 01/11/2020 10:43:19
ID: 960266991
Fulltext: <td class="diff-addedline"><div>In May 2020, the OpenPandemics - COVID-19 partnership between [[Scripps Research]] and IBM's [[World Community Grid]] was launched. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] which will help predict the effectiveness of a particular chemical compound as a possible treatment for COVID-19".</div></td>
Changed Text: <td class="diff-addedline"><div>In May 2020, the OpenPandemics - COVID-19 partnership between [[Scripps Research]] and IBM's [[World Community Grid]] was launched. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] which will help predict the effectiveness of a particular chemical compound as a possible treatment for COVID-19".&lt;ref name=WCG_1&gt;{{cite web| title=OpenPandemics - COVID-19| url=https://www.worldcommunitygrid.org/research/opn1/overview.do| publisher=IBM| date=2020| access-date=18 May 2020}}&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>In May 2020, the OpenPandemics - COVID-19 partnership between Scripps Research and IBM's World Community Grid was launched. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] which will help predict the effectiveness of a particular chemical compound as a possible treatment for COVID-19".</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=985995608&oldid=960266991
Previous Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=960266991&oldid=958741133
Fuzzy: In May 2020, the OpenPandemics—COVID-19 partnership between Scripps Research and IBM's World Community Grid was launched. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] which will help predict the effectiveness of a particular chemical compound as a possible treatment for COVID-19".[41]



POST
FUZZYWUZZY
Title: Impact of the COVID-19 pandemic on science and technology
Date: 01/11/2020 10:43:20
ID: 967891241
Fulltext: <td class="diff-addedline"><div>For coronavirus studies and information that can help enable CS, many more online resources are available through other [[open access]] and [[open science]] websites, including portals run by the [[Cambridge University Press]], the Europe branch of the [[Scholarly Publishing and Academic Resources Coalition]], ''[[The Lancet]]'', [[John Wiley and Sons]], and [[Springer Nature]].</div></td>
Changed Text: <td class="diff-addedline"><div>For coronavirus studies and information that can help enable CS, many more online resources are available through other [[open access]] and [[open science]] websites, including portals run by the [[Cambridge University Press]],&lt;ref name=CUP_1&gt;{{cite web| title=Coronavirus Free Access Collection| url=https://www.cambridge.org/core/browse-subjects/medicine/coronavirus-free-access-collection| publisher=[[Cambridge University Press]]| date=2020| access-date=4 April 2020}}&lt;/ref&gt; the Europe branch of the [[Scholarly Publishing and Academic Resources Coalition]],&lt;ref name=SPARC_1&gt;{{cite web| title=The Coronavirus and Open Science: Our reads and Open use cases| url=https://sparceurope.org/coronaopensciencereadsandusecases| publisher=[[Scholarly Publishing and Academic Resources Coalition]] Europe| date=March 2020| access-date=4 April 2020}}&lt;/ref&gt; ''[[The Lancet]]'',&lt;ref name=TL_1&gt;{{cite web| title=The Lancet COVID-19 Resource Centre| url=https://www.thelancet.com/coronavirus| publisher=[[Elsevier]] Inc.| date=April 2020| access-date=4 April 2020}}&lt;/ref&gt; [[John Wiley and Sons]],&lt;ref name=Wil_1&gt;{{cite web| title=Covid-19: Novel Coronavirus Outbreak| url=https://novel-coronavirus.onlinelibrary.wiley.com| publisher=[[John Wiley &amp; Sons]], Inc.| date=March 2020| access-date=4 April 2020}}&lt;/ref&gt; and [[Springer Nature]].&lt;ref name=Spri_1&gt;{{cite web| title=SARS-CoV-2 and COVID-19| url=https://www.springernature.com/gp/researchers/campaigns/coronavirus| publisher=[[Springer Nature]]| date=2020| access-date=4 April 2020}}&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>For coronavirus studies and information that can help enable CS, many more online resources are available through other open access and open science websites, including portals run by the Cambridge University Press, the Europe branch of the Scholarly Publishing and Academic Resources Coalition, ''The Lancet'', John Wiley and Sons, and Springer Nature.</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=985995608&oldid=967891241
Previous Link: https://en.wikipedia.org//w/index.php?title=Impact_of_the_COVID-19_pandemic_on_science_and_technology&diff=967891241&oldid=966340740
Fuzzy: 
More



